Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

ng and marketing expenses were $360,741 for the three month period ended June 30, 2007, an increase of 33% from $271,246 for the corresponding 2006 period.

General and administrative expenses of $1,248,605 for the second quarter of 2007 were up from $628,366 in the prior year period, primarily based on non-cash stock based compensation expense from options issued in April of 2007, and estimated accrued expenses associated with the delay in filing registration statements from previous preferred offerings

RECENT CORPORATE ACHIEVEMENTS:

Avicena announced plans for a confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) trial after meeting with the Food and Drug Administration (FDA). The confirmatory Phase III trial of the drug candidate, AL-02, for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), follows two completed studies demonstrating a positive trend towards increased survival.

Avicena announced patient enrollment on target in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial. The Phase III trial, sponsored by the NIH's National Institute of Neurological Disorders and Stroke (NINDS), is designed to evaluate the potential of Avicena's lead Parkinson's disease drug candidate, PD-02, in slowing disease progression. This trial will enroll over 1,720 patients and is one of the largest Parkinson's disease trials ever conducted.

Avicena announced advancement of Huntington's disease clinical program into Phase III in early 2008. Based on a dose-ranging study, Avicena selected an optimal dose of its novel drug candidate HD-02 for the treatment of Huntington's disease. The Company plans to initiate a Phase III trial in early 2008.

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust intellectual
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... of what happens on the surface of cells. The ... A group of researchers from Lund University in Sweden ... a large number of vertical nanowires, known as a ... cell and its surroundings takes place through the cell ... the cell together and that largely comprises lipids, built ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
... Immunogen: Synthetic peptide derived from an ... protein. Specificity: Specific for the ... WNT2B/WNT13 proteins. Recognizes both human WNT13A ... Human Rat (positive controls: mouse WNT2B/WNT13-pCMV-tag2-transfected ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic ... the human C35 protein (chromosome 17 open ... Specificity: Specific for the C35 protein. ... band at ~15 kDa band. Reactivity: ...
...
Biology Products: